Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

737 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, Miller M, Shen YK, Kannan A, Li S, DeKlotz C, Papp K. Bissonnette R, et al. Among authors: papp k. N Engl J Med. 2024 Feb 8;390(6):510-521. doi: 10.1056/NEJMoa2308713. N Engl J Med. 2024. PMID: 38324484 Clinical Trial.
The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR. Papp K, et al. J Am Acad Dermatol. 2001 Nov;45(5):665-74. doi: 10.1067/mjd.2001.117850. J Am Acad Dermatol. 2001. PMID: 11606914 Clinical Trial.
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S. Papp K, et al. N Engl J Med. 2018 Oct 4;379(14):1313-1321. doi: 10.1056/NEJMoa1806382. Epub 2018 Sep 11. N Engl J Med. 2018. PMID: 30205746 Free article. Clinical Trial.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, Hunt B, Souberbielle B; NEPTUNE investigators. Papp KA, et al. Br J Dermatol. 2019 Jun;180(6):1352-1360. doi: 10.1111/bjd.17195. Epub 2018 Nov 2. Br J Dermatol. 2019. PMID: 30207587 Free PMC article. Clinical Trial.
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA. Armstrong AW, et al. Among authors: papp ka. Am J Clin Dermatol. 2019 Feb;20(1):155-164. doi: 10.1007/s40257-018-0396-z. Am J Clin Dermatol. 2019. PMID: 30417277 Free PMC article. Clinical Trial.
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A, Igarashi A, Klekotka P, Patel D, Li J, Tuttle J, Morgan-Cox M, Edson-Heredia E, Friedrich S, Papp K; AMAF investigators. Reich K, et al. Among authors: papp k. Br J Dermatol. 2019 Jul;181(1):88-95. doi: 10.1111/bjd.17628. Epub 2019 Apr 17. Br J Dermatol. 2019. PMID: 30734266 Clinical Trial.
737 results